- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Citizens reiterates Market Outperform rating on Rapport Therapeutics stock | 3 | Investing.com | ||
| 07.01. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | 757 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| 07.01. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Goldman Sachs bekräftigt Kaufempfehlung für Rapport Therapeutics nach Studienerfolg bei Epilepsie-Medikament | 11 | Investing.com Deutsch | ||
| 19.12.25 | Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy | 3 | Investing.com | ||
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data | 1 | Investing.com | ||
| 09.12.25 | Starke Studiendaten: H.C. Wainwright hebt Kursziel für Rapport Therapeutics auf 40 $ an | 10 | Investing.com Deutsch | ||
| 08.12.25 | Rapport Therapeutics: Citizens bestätigt "Market Outperform"-Rating nach neuen Studiendaten | 3 | Investing.com Deutsch | ||
| 05.12.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures | 1 | GlobeNewswire (USA) | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09.25 | Truist Securities initiates Rapport Therapeutics stock with Buy rating | 9 | Investing.com | ||
| 11.09.25 | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | 1 | GlobeNewswire (USA) | ||
| 10.09.25 | Rapport Therapeutics prices $250M stock at $26 per share | 2 | Seeking Alpha | ||
| 10.09.25 | Rapport Therapeutics prices $250 million public offering at $26 per share | 2 | Investing.com | ||
| 10.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Pricing of Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics launches $250 million public stock offering | 16 | Investing.com | ||
| 08.09.25 | Rapport Therapeutics, Inc.: Rapport Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.09.25 | Rapport Therapeutics: Stifel hebt Kursziel nach Studienerfolg deutlich auf 56 $ an | 4 | Investing.com Deutsch | ||
| 08.09.25 | Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data | 2 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| IMMUNITYBIO | 8,228 | -0,75 % | ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,038 | -0,29 % | H.C. Wainwright bestätigt Rating für Microbot Medical nach Adoption durch Klinik | ||
| CYTOKINETICS | 53,50 | +0,94 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,426 | -1,44 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CAPRICOR | 23,300 | -1,48 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,240 | -0,96 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,280 | -1,38 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,500 | -1,32 % | Johnson Fistel, PLLP: Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses | San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,26 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 116,00 | +0,87 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations | Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,200 | -4,35 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at Upcoming Investor Conferences | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:
TD Cowen 46th Annual... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,190 | 0,00 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,500 | +3,17 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen |
Das Unternehmen RAPPORT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,39 % bei einem Aktienkurs von 29,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.